Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume – What’s Next?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) saw unusually-strong trading volume on Tuesday . 2,086,578 shares were traded during trading, an increase of 185% from the previous session’s volume of 731,507 shares.The stock last traded at $107.30 and had previously closed at $108.58.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group lifted their price objective on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a research report on Friday, June 26th. B. Riley Financial upped their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Guggenheim raised their target price on shares of Kymera Therapeutics from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Mizuho lifted their price target on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 30th. They issued a “hold” rating and a $120.00 price target on the stock. Twenty analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $125.65.

Kymera Therapeutics Stock Performance

The firm has a fifty day simple moving average of $103.50 and a two-hundred day simple moving average of $89.78. The firm has a market cap of $9.44 billion, a PE ratio of -34.92 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. The business had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company’s revenue for the quarter was up 465.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.95) EPS. Equities analysts forecast that Kymera Therapeutics, Inc. will post -3.78 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Bruce N. Jacobs sold 77,109 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the sale, the chief financial officer owned 244,883 shares of the company’s stock, valued at $28,151,749.68. This represents a 23.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Nello Mainolfi sold 50,000 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at $79,321,592. This trade represents a 6.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,604,813 shares of company stock valued at $387,557,004 in the last three months. Corporate insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares during the period. State of New Jersey Common Pension Fund D purchased a new position in shares of Kymera Therapeutics during the 4th quarter worth about $2,610,000. Maven Securities LTD purchased a new position in shares of Kymera Therapeutics during the 4th quarter worth about $1,167,000. Eagle Health Investments LP bought a new position in Kymera Therapeutics during the 4th quarter valued at about $10,606,000. Finally, Monashee Investment Management LLC bought a new position in Kymera Therapeutics during the 4th quarter valued at about $7,781,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.